

Michael Hornsey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1911801/publications.pdf>

Version: 2024-02-01

26
papers

1,702
citations

394390

19
h-index

526264

27
g-index

28
all docs

28
docs citations

28
times ranked

2371
citing authors

#	ARTICLE	IF	CITATIONS
1	Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 135-139.	3.0	4
2	Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infectionsâ€™ authorsâ€™ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2713-2713.	3.0	11
3	Characterization of a colistin-resistant Avian Pathogenic <i>Escherichia coli</i> ST69 isolate recovered from a broiler chicken in Germany. <i>Journal of Medical Microbiology</i> , 2019, 68, 111-114.	1.8	9
4	Restoring the activity of the antibiotic aztreonam using the polyphenol epigallocatechin gallate (EGCG) against multidrug-resistant clinical isolates of <i>Pseudomonas aeruginosa</i> . <i>Journal of Medical Microbiology</i> , 2019, 68, 1552-1559.	1.8	20
5	Effects of In vivo Emergent Tigecycline Resistance on the Pathogenic Potential of <i>Acinetobacter baumannii</i> . <i>Scientific Reports</i> , 2018, 8, 4234.	3.3	9
6	Novel Antibacterials: Alternatives to Traditional Antibiotics. <i>Advances in Microbial Physiology</i> , 2018, 73, 123-169.	2.4	48
7	In vitro and In vivo Activity of Theaflavinâ€™Epicatechin Combinations versus Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Infectious Diseases and Therapy</i> , 2017, 6, 435-442.	4.0	25
8	Deletions in a ribosomal protein-coding gene are associated with tigecycline resistance in <i>Enterococcus faecium</i> . <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 572-575.	2.5	32
9	<i>In Vitro</i> and <i>In Vivo</i> Activities of Tigecycline-Colistin Combination Therapies against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3541-3546.	3.2	50
10	In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 343-346.	2.5	25
11	Genetic characterization of tigecycline resistance in clinical isolates of <i>Enterobacter cloacae</i> and <i>Enterobacter aerogenes</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1011-1018.	3.0	48
12	Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. <i>Journal of Medical Microbiology</i> , 2013, 62, 1823-1827.	1.8	117
13	P317 Isolation and characterisation of a novel <i>Nesterenkonia</i> species from a human bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, S141-S142.	2.5	2
14	In vivo efficacy of telavancin/colistin combination therapy in a <i>Galleria mellonella</i> model of <i>Acinetobacter baumannii</i> infection. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 285-287.	2.5	42
15	In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1291-1294.	2.9	24
16	Evaluation of three selective chromogenic media, CHROMagar ESBL, CHROMagar CTX-M and CHROMagar KPC, for the detection of <i>Klebsiella pneumoniae</i> producing OXA-48 carbapenemase: Table 1. <i>Journal of Clinical Pathology</i> , 2013, 66, 348-350.	2.0	27
17	<i>In Vitro</i> Activity of Telavancin in Combination with Colistin versus Gram-Negative Bacterial Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3080-3085.	3.2	56
18	De-escalation of antimicrobial therapy in Gram-negative sepsis: easier said than done?. <i>Critical Care</i> , 2011, 15, .	5.8	1

#	ARTICLE	IF	CITATIONS
19	Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of <i>Acinetobacter baumannii</i> Mediated by the pmrAB Two-Component Regulatory System. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3370-3379.	3.2	354
20	Whole-genome comparison of two <i>Acinetobacter baumannii</i> isolates from a single patient, where resistance developed during tigecycline therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1499-1503.	3.0	96
21	<i>In Vivo</i> Efficacy of Glycopeptide-Colistin Combination Therapies in a <i>Galleria mellonella</i> Model of <i>Acinetobacter baumannii</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3534-3537.	3.2	113
22	A Novel Variant, NDM-5, of the New Delhi Metallo- β -Lactamase in a Multidrug-Resistant <i>Escherichia coli</i> ST648 Isolate Recovered from a Patient in the United Kingdom. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5952-5954.	3.2	312
23	In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1047-1051.	3.0	74
24	Tigecycline resistance in <i>Serratia marcescens</i> associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 479-482.	3.0	32
25	AdeABC-mediated efflux and tigecycline MICs for epidemic clones of <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1589-1593.	3.0	129
26	Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of <i>Enterobacter cloacae</i> during ciprofloxacin treatment. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 478-481.	2.5	36